The cell and gene therapy boom is running into its manufacturing bill. Traditional production remains manual and expensive, which makes the ROI for many therapies murky at best. Venture funding in the sector has plunged more than 80% from its 2021 peak. Cellares is betting the path forward is industrial. The South San Francisco company…
Biotech bounce back possible, but when?
The biotech industry continues to be in something of a “hangover period” where everyone realizes that there was “probably just a little bit too much enthusiasm” in circa 2020 and 2021, said Matthias Kleinz, DVM, Ph.D., executive vice president, translational sciences at UPMC Enterprises, the innovation and commercialization arm of University of Pittsburgh Medical…

